Arkhangelsk Clinical Tuberculosis Dispensary in Arkhangelsk, northern Russia, January 2020.


In Russia, MSF is collaborating with health authorities and academic partners in Arkhangelsk region to reduce the burden of drug-resistant tuberculosis (DR-TB) and improve treatment for the disease.

Working in line with the latest World Health Organization recommendations for DR-TB, our teams in Russia began providing drugs and technical advice to support the treatment of patients with the most severe forms of TB in Arkhangelsk region in January. By the end of the year, we had supported the treatment of 23 patients. In partnership with Arkhangelsk Regional Ministry of Health, Northern State Medical University and Arkhangelsk Clinical TB Dispensary, we are building on existing expertise and working together to implement novel all-oral short-course regimens. The aim of the collaboration is to provide evidence for future developments in TB policy in Russia and increase the availability of more effective models of treatment.  

Our teams have been working in Russia since the early 1990s, running programmes in Moscow, Saint Petersburg, Kemerovo region, Chechnya, Ingushetia and Dagestan.  

Read full article in International Activity Report 2019

Our related news